AIM ImmunoTech (AIM) Debt Ratio (2011 - 2026)

AIM ImmunoTech's (AIM) quarterly Debt Ratio came in at 0.02 in Q1 2026, down 84.74% on a QoQ basis from 0.16 in Q4 2025.

AIM ImmunoTech (AIM) Debt Ratio (2011 - 2026) Analysis & Trends

AIM ImmunoTech (AIM) has 11 years of Debt Ratio data on file, last reported at 0.02 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02 (changed N/A YoY) and the FY2025 annual result came in at 0.16, changed N/A from the prior year.
Debt Ratio eased to 0.02 in Q1 2026, from 0.16 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.16 in Q4 2025 to a low of 0.01 in Q3 2024.
A 3-year average of 0.05 and a median of 0.02 in 2026 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	AIM ImmunoTech	4.43 Mn	-5.53 Mn	21,000.00	-

Download Data